A cost-effectiveness model found semaglutide 2.4 mg to be a clinically beneficial and economically viable treatment option for patients with non-cirrhotic metabolic dysfunction‐associated steatohepatitis (MASH) with moderate to advanced...
A cost-effectiveness model found semaglutide 2.4 mg to be a clinically beneficial and economically viable treatment option for patients with non-cirrhotic metabolic dysfunction‐associated steatohepatitis (MASH) with moderate to advanced...
In a cost-effective analysis of pharmacotherapies, semaglutide and tirzepatide demonstrated better cost-effectiveness than standard of care among patients with metabolic dysfunction‐associated steatohepatitis (MASH).
In a cost-effective analysis of pharmacotherapies, semaglutide and tirzepatide demonstrated better cost-effectiveness than standard of care among patients with metabolic dysfunction‐associated steatohepatitis (MASH).
